London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
straight from open
I've never seen one of those actually work out correct but hopefully not the case here!
Ovoca Bio Plc (OVB.LN)
12.500 +0.250 (+2.04%) 09/16/19 [LSE]
BARCHART OPINION for Mon, Sep 16th, 2019
0.12 euros is about 11p??
ST... your link shows a price of 11p
ShareCast and Alliance News are reporting contradictory information regarding the company's loss. I guess it pays to read the RNS for yourself.
MY mistake it is Frankfurt but its flying over there
Unfortunately this shows the ill informed rubbish spouted which actually detracts from the value case here.
Fra is the Frankfurt exchange, not France. A pretty basic error if you know your stuff and no sign it's going through 17p there...
Best time to top up when it's quiet :-)
nice 24k buy this should be circa 30p on cash/investment alone never mind multiple patents granted
The Company remains in a strong financial position and has sufficient funds to meet its current needs. As of 30 June 2019, cash and liquid investments were recorded at a fair value of €16.5 million ($19.7 million)
Market cap 10 million.....
We again thank Yuri Radchenko and Nikolay Myasoyedov for their greatly valued services to the Board, while noting that Nikolay will continue to serve as a non-executive director at IVIX.
The Company remains in a strong financial position and has sufficient funds to meet its current needs. As of 30 June 2019, cash and liquid investments were recorded at a fair value of €16.5 million ($19.7 million). Over the course of the reporting period, we took advantage of the strength in our equity securities portfolio by disposing of a proportion of the portfolio to help fund our future development plans for BP-101. During the period, the Company sold 170,000 shares in Polymetal International plc (LSE:POLY) and made select disposals of a number of other equity securities. The net proceeds from these sales amounted to approximately €3.0 million ($3.4 million). These transactions have contributed to the increase in comprehensive income during the period, from a loss of €4.3 million ($5.7 million) in the first half of 2018 to comprehensive income of €2.2 million ($2.3 million) over the same period in 2019. Dividend income received during the period was €0.28 million ($0.32 million), arising from our holdings in Polymetal International shares.
Ovoca Bio plc continues to have a sound capital base and will use this to support the exciting development of BP-101 in HSDD, both in its anticipated first commercial market of the Russian Federation followed by Europe and the US, subject to regulatory approval. Your Board remains highly optimistic for the future of the Company and is committed to creating value for our shareholders. I would like to thank our employees and partners for enabling the strong progress in the first half of the year as we continue our journey towards becoming a successful biotechnology company meeting the unmet medical needs of patients suffering from female sexual dysfunction.
Ovoca Bio, a biopharmaceutical company focused on identifying and developing novel therapeutics targeting the large unmet needs in the treatment of female sexual dysfunction, is pleased to announce its interim financial statements and report covering the six-months ending 30 June 2019.
Please click on the following link to view the full Half Year Report:
· Completion of a Phase 3 study in Russia of drug candidate BP-101 in the treatment of female sexual dysfunction, showing statistically significant improvement in primary and key secondary endpoints;
· Acquisition of an additional interest in IVIX LLC ("IVIX"), increasing Ovoca's overall holding in IVIX to 59.9%;
· Cash and liquid investments at fair value of €16.5 million ($19.7 million) as at 30 June 2019;
· Total comprehensive income for the first six-months of 2019 of €2.2 million ($2.3 million); and
· During the period, the Company disposed of a portion of its investment portfolio. The net proceeds from the sales amounted to approximately €3.0 million ($3.4 million).
In the first half of 2019 Ovoca Bio made significant progress towards our goal of becoming a leader in the treatment of female sexual dysfunction. As previously reported, our subsidiary IVIX completed a successful Phase 3 trial in Russia of the novel peptide nasal spray, BP-101, in patients with the medical condition known as hypoactive sexual desire disorder (or "HSDD"), a condition characterized by a distressing lack or loss of sexual desire. The study confirmed earlier clinical results and demonstrated significant improvement in primary, as well as key secondary, endpoints. The Company also increased its shareholding in IVIX to 59.9%, the maximum available at this time under its purchase option with the previous owners.
In parallel with, and subsequent to, these major milestones, preparations have been underway for regulatory interactions concerning BP-101 with the health authorities in the Russian Federation, Germany and the USA. On 12 September 2019, we were pleased to announce the submission of a marketing authorisation application for BP-101 with the Russian Ministry of Health. If approved, BP-101 could be available for marketing in the Russian Federation towards the end of 2020. In the coming months we intend to continue conversations with the FDA in the United Stated and commence them with the Federal Institute for Drugs and Medical Devices in Germany as we pursue our international development plans for BP-101. We look forward to providing further updates on our progress in due course.
With the strategic shift in direction of the Company from its historic roots in natural resources, there have been a number of Board changes and we anticipate there will be more in the future to support our growing status
Further announcements from many other countries confirming their Patents rights.
Whilst awaiting US and UK, OVB will be busy negotiating production options with a JV as it clearly stated it wants to become a Manufacturer too. We are expecting news confirming the market strategy plan of all those Countries that are further forward in accepting Libicore supplies. The more Patents approval being announced the closer production needs to start. Manufacturing 100's M dose's needs to commence to fulfil the demands Worldwide. Stock piling needs to commence together with a Mega marketing campaign.
I personally see this too big of a tall order to execute from OVB and therefore a Major Buyout of the Patent is more likely.
This can happen at any time. Still a Bargain if you consider £35M-£50M plus for a worldwide Patent rights in a £BN market.
Major Companies are no doubt in secret discussions at this early stage. Offer at a low value mention than pay £100M plus in the near future.
OVB are in and will be in a commanding position to negotiate favourable terms.
Was disappointed to see the market reaction to the positive milestone RNS'd this morning. Can anyone tell me what other countries this drug is making progress with? Has there been any interest or talks with any potential partnering pharm companies?
Interims over the next two weeks too!
Will be showing a good £14-15mil in the bank
What’s the mcap? Lol.
You do the maths, we have more cash/asset than mcap let alone libicore! The IP must be worth double mcap alone, let alone commercial aspect and cash in bank
Patents coming through 1 by 1 KEEP UP the great work
They are also pushing EU and global commercial deals and marketing, so they won’t be standing still that’s for sure
Trial stopped early, that’s how good this drug is. Certain to be approved for commercial market next year
Patents coming through 1 by 1
Will be interesting to see how the market reacts to this latest piece of news, if it bothers to react at all. It's at least a 12 month wait for the outcome. I understand other things are going on in the meantime though.
#OVB the great thing about this one is...
1. <£10m Mcap
2. <100m shares in issue
3. <5% free float
4. #POLY shares = c£16m
5. Nil value for Libicore
6. Stage III drug
7. Marketing from 2020
8. Global addressable market
9. Big Pharma JV interest?